As a member of the College of Fellows it is your privilege to elect the 2019 College of Fellows inductees. The Selection Committee has completed the review of credentials and eligibility to the College and now await your vote of the candidates listed below. The Controlled Release Society Policy & Procedure states: "Election of Fellows shall be determined by electronic ballot sent to all members of the College. Election shall be by affirmative vote on at least 75% of ballots cast for the candidate."
Elevation to ‘fellow’ recognizes an exceptional individual in the field of controlled release who has made outstanding and sustained contributions to the field of delivery science and technology. In considering your vote for fellow status, consider the length, breadth, depth and impact of the achievements. Fellow candidates working in academia, industry or governmental agencies, and representative of all demographic groups are selected from every area of delivery science and technology. Fellows should have distinguished themselves as leaders in their field through contributions in fundamental or applied research, technology, products, and/or education that have impacted the areas of interest of the CRS.
Please complete your ballot no later than Friday, April 15, 2019.
Candidates
Christine Allen, PhD - Dr. Allen is a Professor and GSK Chair in Pharmaceutics and Drug Delivery at the University of Toronto (UofT) where she leads a highly productive research program focused on development of advanced drug formulations. Her research has yielded > 130 publications with several featured in journal covers and editorials. She is committed to the commercialization of her research, with a number of innovations moving towards clinical development. She has held significant leadership roles at UofT (i.e. currently serving as interim Dean of her Faculty) and has been a highly impactful and dedicated member of CRS, serving as Director, Secretary and Treasurer on the Board and AMPC co-Chair.
Tatiana Branich, PhD - Dr. Bronich is a Parke-Davis Professor of Pharmaceutical Sciences at the University of Nebraska Medical Center. Her major scientific contributions are in the areas of synthetic and biological macromolecules, polymer micelles and complexes, and drug delivery systems. Of special interest is the design and study of novel types of bio-functional nanostructures utilizing a combination of supramolecular assembly and covalent chemical reactions, and application of these materials in drug delivery to treat cancer and infectious diseases. She published over 110 peer-reviewed papers, her work was cited 8409 times (Hirsh index 47). Her research is supported by grants from NIH. She is a Director of the NIH-supported Center of Biomedical Research Excellence “Nebraska Center for Nanomedicine” and Co-Director of the Center for Drug Delivery and Nanomedicine at the University of Nebraska Medical Center. She is an elected Fellow of AIMBE and is currently serving as Editor-of-Chief of “Nanomedicine: Nanotechnology, Biology and Medicine” journal.
Patrick Couvreur, PhD - Dr. Couvreur is a Full Professor of Pharmacy at Paris-Saclay University, member of the Académie des Sciences and holder of the chair of “Innovations Technologiques” (2009-2010) at the prestigious Collège de France. Prof Couvreur’s contributions in the field of drug delivery and nanomedicine are highly recognized around the world with over 550 publications (Google Scholar H-index 127 and 69,000 citations). He founded two start-up companies (Bioalliance, entering the stock market in 2005 and Medsqual) and developed an anticancer nanomedicine reaching phase III clinical trial. His scientific contribution is recognized by numerous international awards. Apart from the Académie des Sciences, he is also appointed as a foreign member of US National Academies of Engineering and Medicine. By a decree of the President of the French Republic, Patrick Couvreur is appointed as “Chevalier de la Légion d’Honneur.
Paula Hammond, PhD - Dr. Hammond is the David H. Koch Chair Professor of Engineering at the Massachusetts Institute of Technology, Head of the Department of Chemical Engineering and a member of MIT’s Koch Institute for Integrative Cancer Research. Her research in nanomedicine encompasses the development of new biomaterials to enable drug delivery from surfaces with spatio-temporal control. She also investigates novel responsive polymer architectures for targeted nanoparticle drug and gene delivery. Professor Paula Hammond was elected into the National Academy of Engineering in 2017, the National Academy of Medicine in 2016, and the 2013 Class of the American Academy of Arts and Sciences.
Uday B. Kompella, PhD, FAAPS, FARVO - Dr. Kompella is a Professor of Pharmaceutical Sciences, Ophthalmology, and Bioengineering at the University of Colorado and Co-director of the Colorado Center for Nanomedicine and Nanosafety. He has 25 years of faculty experience, about 200 publications focused mainly on ocular drug delivery (h-index: 54), and over 230 invited presentations. He consulted for over 40 organizations and served as an editor for four journals, including Expert Opinion on Drug Delivery (Editor-in-Chief, 8 years) and Pharmaceutical Research (Editor, 10+ years). He received $12M NIH/FDA funding as a principal investigator. Dr. Kompella received Distinguished Scientist, Distinguished Teacher, Dean’s Mentor, Innovations in Science, and ARVO Translational Ophthalmology Research Awards. He is also co-founder of Ocugen, a company developing protein-, gene-, and nano- medicines with two ongoing Phase 3 trials.
Ravi Kumar, PhD - Dr. N.V. Ravi Kumar received his PhD in Drug Delivery from Indian Institute of Technology, Roorkee, in 2000. Prior to joining TAMU on 11/2013, he was the professor of drug delivery at University of Strathclyde, Glasgow-UK, and Assistant Professor at National Institute of Pharmaceutical Education and Research, India. His research has won him several awards including the T. Nagai “Outstanding Researcher Advisor” by Controlled Release Society, USA, 2018; named as one of the Royal Society of Chemistry’s, Faces of Toxicology, UK, 2017; the British Pharmaceutical Conference Science Medal, UK 2009; Tom Gibson Memorial Award by British Society of Plastic Surgeons & the Royal College of Physicians and Surgeons, UK 2008; Indian National Science Academy Medal for Young Scientists, India 2007. He is elected a Fellow, American Association of Pharmaceutical Scientists (AAPS). He has been nominated to become a member of the Controlled Release Society College of Fellows, for his long association and service to the CRS and innovation in drug delivery based on outside the box periodic-functional polyesters and non-competitive targeting strategies.
Priyabrata Mukherjee, PhD - Dr. Mukherjee is Professor of Pathology and Peggy and Charles Stephenson Endowed Chair in Laboratory Cancer Research at the University of Oklahoma Health Sciences Center. He serves as Associate Director for Translational Research at the NCI designated Stephenson Cancer Center. His pioneering discoveries in materials science, nanomedicine and cancer are used in numerous applications in various diseases including cancer, ocular disease and rheumatoid arthritis. He is among one of the pioneers that first described the biological synthesis of metal and metal sulfide nanoparticles. Dr. Mukherjee has revolutionized the area of biological and ecofriendly synthesis of nanoparticles. His original work on extracellular biosynthesis of silver nanoparticles are cited more than 1400 times and more than 13000 in total with h index of 50. He holds 5 US patents and 1 international patent that have been licensed to Psimedica Ltd (Malvern, UK). He has published >100 peer-reviewed articles and 4 book chapters, serves as associate editor/editorial board member of 11 international journals. Because of his pioneering research on nanomedicine and metabolism, NIH has awarded him 3 investigator initiated multimillion dollar research project grants (R01).
Richard J. Price, PhD - Dr. Price is a Professor of Biomedical Engineering and Radiology & Medical Imaging at UVa. He has pioneered the use of MRI-guided focused ultrasound for nanoparticle delivery across the blood-brain barrier, and his research underpins the first ever clinical trial combining thermal focused ultrasound with immunotherapy for treating metastatic breast cancer. He has received the Andrew Lockhart Memorial Award for Focused Ultrasound Cancer Research and the Jorge Heller “Outstanding Paper” Award from the Controlled Release Society. He is also Research Director of the UVa Focused Ultrasound Center, Director of the UVa Beckman Scholars Program, and a Fellow of AIMBE.
Yasuhiko Tabata, PhD - Dr. Tabata is Professor and Chairman of the Laboratory of Biomaterials at the Institute for Frontier Life and Medical Sciences, Kyoto University and a Professor of the Graduate School of Medicine, Osaka University, and guest professors at the Graduate School of Medicine, Dentistry, Pharmaceutical Sciences, and Engineering of 17 different universities. He received his BD in Polymer Chemistry (1981), Ph.D. (1988) in Technology, D.Med.Sc. (2002), and D.Pharm. (2003) all at Kyoto University. He was a Visiting Scientist at the MIT (Professor Robert Langer) (1991-92). He has published 1,550 scientific papers including 145 book chapters and review articles and has 130 patents. He has received many prestigious awards in the field. His research focuses on the design and preparation of biodegradable or non-biodegradable biomaterials for their biological, medical, and pharmaceutical applications, while the keywords are biomaterials, drug delivery system (DDS), tissue engineering, regenerative medicine, stem cell technology, and medical diagnostics.
